$
201.120
+2.48(1.248%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
201.530
Open
199.760
VWAP
200.24
Vol
1.35M
Mkt Cap
350.91B
Low
199.2108
Amount
270.30M
EV/EBITDA(TTM)
15.44
Total Shares
1.77B
EV
414.97B
EV/OCF(TTM)
21.52
P/S(TTM)
6.03
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
15.58B
+7.74%
3.269
+8.96%
16.33B
+8.15%
3.323
+53.82%
14.44B
+8.22%
2.923
+18.83%
Estimates Revision
The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 1.31% over the past three months. During the same period, the stock price has changed by 6.98%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.31%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.33%
In Past 3 Month
Stock Price
Go Up
up Image
+6.98%
In Past 3 Month
16 Analyst Rating
up Image
7.01% Upside
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 215.21 USD with a low forecast of 170.00 USD and a high forecast of 255.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
6 Hold
0 Sell
Moderate Buy
up Image
7.01% Upside
Current: 201.120
sliders
Low
170.00
Averages
215.21
High
255.00
Piper Sandler
David Amsellem
Overweight
initiated
$231
2025-08-12
New
Reason
Piper Sandler analyst David Amsellem assumed coverage of AbbVie with an Overweight rating and $231 price target. The company is in an "enviable position" as it does not face a major loss of exclusivity through the end of the decade, the analyst tells investors in a research note. Piper believes AbbVie's visibility into continued sales and EBITDA growth through the end of the decade is high with Skyrizi and Rinvoq expansion, visibility into growth for the oncology segment, and a durable neuromodulator franchise.
Daiwa
Neutral -> Outperform
upgrade
$214
2025-08-07
Reason
Daiwa upgraded AbbVie to Outperform from Neutral with a $214 price target.
Raymond James
Outperform
maintain
$227 -> $236
2025-08-01
Reason
Raymond James raised the firm's price target on AbbVie to $236 from $227 and keeps an Outperform rating on the shares. AbbVie delivered a very solid Q2 with nice top- and bottom-line beats, and raised 2025 guidance for the second time this year driven by the strong momentum with most key growth drivers like Skyrizi and Neuro, the analyst tells investors in a research note. Aesthetics was soft as anticipated and continues to be hampered by macro headwinds that are persisting, so it's prudent to remain cautious with that franchise though AbbVie is still optimistic it will turn around longer-term, the firm says.
Evercore ISI
Gavin Clark-Gartner
Outperform
maintain
$205 -> $207
2025-08-01
Reason
Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on AbbVie to $207 from $205 and keeps an Outperform rating on the shares. AbbVie showed strong confidence in their neuro franchise, with positive sentiment around early-stage business development, while the reported, potential Gilgamesh acquisition could be "a boon for the psychedelics sector, with positive regulatory signals and strong data translating across mechanisms of action," the analyst tells investors.
Guggenheim
Buy
maintain
$216 -> $227
2025-08-01
Reason
Guggenheim raised the firm's price target on AbbVie to $227 from $216 and keeps a Buy rating on the shares following what the firm calls "another strong quarter." Management raised full-year revenue and EPS guidance for the second time this year, adds the analyst, who update the firm's model to reflect higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates.
Citi
Buy
to
Neutral
downgrade
$210 -> $205
2025-05-14
Reason
Citi downgraded AbbVie to Neutral from Buy with a price target of $205, down from $210. While the company's current fundamentals are solid, the share impact from quarterly surprises could diminish going forward, especially as investors increasingly shift more focus to AbbVie's pipeline, the analyst tells investors in a research note. Citi cites the company's "comparatively lighter late-stage" pipeline versus its biopharma peers and a higher perceived policy risk than peers for the downgrade. Both of these add risk to AbbVie's "relative safety positioning," contends the firm.

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 15.12, compared to its 5-year average forward P/E of 12.30. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.30
Current PE
15.12
Overvalued PE
15.27
Undervalued PE
9.33

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average EV/EBITDA
11.60
Current EV/EBITDA
13.77
Overvalued EV/EBITDA
13.57
Undervalued EV/EBITDA
9.64

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
4.62
Current PS
5.59
Overvalued PS
5.52
Undervalued PS
3.71

Financials

Annual
Quarterly
FY2025Q2
YoY :
+6.65%
15.42B
Total Revenue
FY2025Q2
YoY :
+17.44%
5.85B
Operating Profit
FY2025Q2
YoY :
-31.46%
941.00M
Net Income after Tax
FY2025Q2
YoY :
-32.47%
0.52
EPS - Diluted
FY2025Q2
YoY :
+140.59%
4.88B
Free Cash Flow
FY2025Q2
YoY :
+1.24%
71.82
Gross Profit Margin - %
FY2025Q2
YoY :
-3.28%
31.27
FCF Margin - %
FY2025Q2
YoY :
-35.72%
6.10
Net Margin - %
FY2025Q2
YoY :
-0.52%
9.51
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.6M
USD
1
3-6
Months
25.7M
USD
5
6-9
Months
32.4M
USD
6
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
76.0K
Volume
20
6-9
Months
192.1K
Volume
27
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
26.4K
Volume
Months
6-9
17
2.1M
Volume
Months
0-12
1
57.3K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
174.0K
USD
5
6-9
Months
0.0
USD
0
0-12
Months
8.0K
USD
1
Bought
0-3
1
8.0K
USD
Months
3-6
12
120.5K
USD
Months
6-9
6
115.0K
USD
Months
0-12
3
24.0K
USD
Months

ABBV News & Events

Events Timeline

2025-08-12 (ET)
2025-08-12
13:00:54
AbbVie announces $195M investment to expand API manufacturing in U.S.
select
2025-08-07 (ET)
2025-08-07
07:55:43
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
select
2025-07-31 (ET)
2025-07-31
13:50:21
Trump posts letters calling on drug company CEOs to lower prices
select
link
Sign Up For More Events

News

8.5
00:00 AMNASDAQ.COM
PinnedAbbVie To Invest $195 Mln In Illinois API Manufacturing Expansion
8.5
08-12SeekingAlpha
PinnedAbbVie to invest $195M to build plant in Illinois
6.5
08-12MarketWatch
Stocks too expensive for you? This bargain-hunting strategy can yield big returns with less risk.
Sign Up For More News

FAQ

arrow icon

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 201.12 USD — it has increased 1.25 % in the last trading day.

arrow icon

What is AbbVie Inc (ABBV)'s business?

arrow icon

What is the price predicton of ABBV Stock?

arrow icon

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

arrow icon

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

arrow icon

How many employees does AbbVie Inc (ABBV). have?

arrow icon

What is AbbVie Inc (ABBV) market cap?